A Phase 1B Study of RMC-6291 Plus RMC-6236 in People With Advanced Cancer

Full Title

Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced KRAS G12C-Mutated Solid Tumors

Purpose

Researchers want to find the best doses of RMC-6291 and RMC-6236 when given together to treat lung cancer and other types of cancer that have KRAS G12C mutations. The people in this study have advanced non-small cell lung cancer (NSCLC) or colorectal cancer with a gene mutation (change) called KRAS G12C.

RMC-6291 and RMC-6236 work in different ways to block the effects of the mutated KRAS G12C protein. This protein sends signals that cause cancer cells to grow. By blocking these signals, RMC-6291 and RMC-6236 may help slow or stop the growth of your cancer. Both drugs are taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.